NEW YORK May 22 Wyeth WYE.N and Progenics
Pharmaceuticals Inc (PGNX.O) said on Thursday that an
intravenous form of their Relistor drug failed to meet its main
goal in a late-stage study for addressing gastrointestinal
issues following surgery.
The Phase 3 study, which also failed to meet secondary
goals, confirms earlier findings of the drug used for the
condition, known as post-operative ileus. Progenics and Wyeth
said they would study the results to determine whether to
continue development of the intravenous form and this use.
The companies also said a mid-stage study of an oral form
of Relistor for the treatment of opioid-induced constipation
showed positive activity. The Phase 2 trial involved 122
patients with chronic, non-malignant pain such as back pain or
osteoarthritis. Another Phase 2 trial of the oral formulation
Last month, an injection form of Relistor won U.S. approval
for relieving constipation that often occurs with the use of
morphine or other opioid painkillers. The drug is the first
approved product for Progenics.
(Reporting by Lewis Krauskopf, editing by Maureen Bavdek and
Lisa Von Ahn)